Mphasis: HSBC on Mphasis Maintains Buy with target price of Rs 2780; highlights launch of Tria to shift from services to a platform-plus-outcomes model tracked via ARR, while strong AI demand pushed TTM TCV above USD 2 bn, supporting high single- to double-digit FY26-28 revenue growth outlook, with valuations still seen as reasonable amid improving growth trajectory.

 29 May 2026 09:04 AM

Mphasis: HSBC on Mphasis Maintains Buy with target price of Rs 2780; highlights launch of Tria to shift from services to a platform-plus-outcomes model tracked via ARR, while strong AI demand pushed TTM TCV above USD 2 bn, supporting high single- to double-digit FY26-28 revenue growth outlook, with valuations still seen as reasonable amid improving growth trajectory.

Mphasis: Nomura on Mphasis Maintains Buy with target price of Rs 2620; says Mphasis is focusing on an “agency model” to strengthen its AI positioning, leveraging large-deal teams to drive deal wins, revamping delivery at scale for the new AI paradigm, maintaining disciplined capital allocation while investing for growth, and pivoting towards a more outcome-based business model.

 29 May 2026 09:04 AM

Mphasis: Nomura on Mphasis Maintains Buy with target price of Rs 2620; says Mphasis is focusing on an “agency model” to strengthen its AI positioning, leveraging large-deal teams to drive deal wins, revamping delivery at scale for the new AI paradigm, maintaining disciplined capital allocation while investing for growth, and pivoting towards a more outcome-based business model.

Mphasis: JPMorgan Chase & Co. maintains Overweight on Mphasis with TP of ₹2,650; key Analyst Day takeaways: AI adoption in brownfield enterprise projects remains complex, launch of AI platform Tria with subscription/implementation/managed-services pricing, stronger go-to-market execution driving larger multi-year transformation deals, aggressive vendor-consolidation “buyout” strategy, and transition from a pure services model to a platform + outcome-based model by FY27 with new metrics like ARR, platform attach rate and NRR from FY28.

 29 May 2026 09:04 AM

Mphasis: JPMorgan Chase & Co. maintains Overweight on Mphasis with TP of ₹2,650; key Analyst Day takeaways: AI adoption in brownfield enterprise projects remains complex, launch of AI platform Tria with subscription/implementation/managed-services pricing, stronger go-to-market execution driving larger multi-year transformation deals, aggressive vendor-consolidation “buyout” strategy, and transition from a pure services model to a platform + outcome-based model by FY27 with new metrics like ARR, platform attach rate and NRR from FY28.

Mphasis: Citigroup maintains Neutral on Mphasis with target price of ₹2,310; management unveiled AI platform Tria to drive enterprise AI adoption and outcome-based transformation, aiming to capture emerging AI-led demand through governed and economic AI solutions, while Citi stays cautious on the IT services sector amid uncertainty over AI’s medium/long-term impact on growth and valuations.

 29 May 2026 09:04 AM

Mphasis: Citigroup maintains Neutral on Mphasis with target price of ₹2,310; management unveiled AI platform Tria to drive enterprise AI adoption and outcome-based transformation, aiming to capture emerging AI-led demand through governed and economic AI solutions, while Citi stays cautious on the IT services sector amid uncertainty over AI’s medium/long-term impact on growth and valuations.

Mphasis: Unveils Mphasis Tria, Backed by Front2BackTM, Boosting Mphasis' Transformation into a Platform-Focused AI Co.

 27 May 2026 02:37 PM

Mphasis: Unveils Mphasis Tria, Backed by Front2BackTM, Boosting Mphasis' Transformation into a Platform-Focused AI Co.

Mphasis: Co partners with Indian School of Business (ISB) to establish an ‘AI Hub’ || Co F1 Foundation will invest ~ INR 20 crore over the next four years || The hub to drive various Impactful AI initiatives across healthcare and finance sectors

 22 May 2026 07:54 AM

Mphasis: Co partners with Indian School of Business (ISB) to establish an ‘AI Hub’ || Co F1 Foundation will invest ~ INR 20 crore over the next four years || The hub to drive various Impactful AI initiatives across healthcare and finance sectors

MPHASIS: Q4 CONS NET PROFIT 5.1B RUPEES VS 4.4B (QOQ) || Q4 REVENUE 42B RUPEES VS 40B (QOQ)

 29 Apr 2026 11:56 PM

MPHASIS: Q4 CONS NET PROFIT 5.1B RUPEES VS 4.4B (QOQ) || Q4 REVENUE 42B RUPEES VS 40B (QOQ)

MPHASIS: Q4 EBIT 6.5B RUPEES VS 6.1B (QOQ) || Q4 EBIT MARGIN 15.38% VS 15.21% (QOQ)

 29 Apr 2026 11:56 PM

MPHASIS: Q4 EBIT 6.5B RUPEES VS 6.1B (QOQ) || Q4 EBIT MARGIN 15.38% VS 15.21% (QOQ)

MPHASIS: CO BOARD RECOMMENDS FINAL DIVIDEND OF ₹62 PER SHARE

 29 Apr 2026 11:57 PM

MPHASIS: CO BOARD RECOMMENDS FINAL DIVIDEND OF ₹62 PER SHARE

Mphasis: CLSA on Mphasis Hold, Target Price Rs 2219 as inconsistent growth, high dependence on US BFSI, limited diversification, and leakage in base business offset deal wins, with stable mid-teen margins but limited operating leverage.

 25 Mar 2026 08:57 AM

Mphasis: CLSA on Mphasis Hold, Target Price Rs 2219 as inconsistent growth, high dependence on US BFSI, limited diversification, and leakage in base business offset deal wins, with stable mid-teen margins but limited operating leverage.

MPHASIS: Jefferies Downgrade MPHASIS to Hold, Target Price cut to Rs 2450 from Rs 3410

 23 Feb 2026 09:13 AM

MPHASIS: Jefferies Downgrade MPHASIS to Hold, Target Price cut to Rs 2450 from Rs 3410

Mphasis: Co Ceo Says - See AI Deals Stemming From Banking, Airlines And Healthcare

 23 Jan 2026 12:16 PM

Mphasis: Co Ceo Says - See AI Deals Stemming From Banking, Airlines And Healthcare

Mphasis: Nomura on Mphasis Neutral, target price Rs 2970

 23 Jan 2026 09:12 AM

Mphasis: Nomura on Mphasis Neutral, target price Rs 2970

Mphasis: HSBC on Mphasis Buy, target price Rs 3350

 23 Jan 2026 09:12 AM

Mphasis: HSBC on Mphasis Buy, target price Rs 3350

Mphasis: Jefferies on Mphasis Buy, target price Rs 3410

 23 Jan 2026 09:12 AM

Mphasis: Jefferies on Mphasis Buy, target price Rs 3410

Mphasis: Motilal Oswal on Mphasis Maintain BUY with a target price of ₹3,900

 23 Jan 2026 09:12 AM

Mphasis: Motilal Oswal on Mphasis Maintain BUY with a target price of ₹3,900

Mphasis: Guidance - Management expects Q4 FY26 to be the strongest sequential growth quarter for the year, aligning with their guidance of achieving greater than 2x industry growth.- Concall Update

 23 Jan 2026 08:51 AM

Mphasis: Guidance - Management expects Q4 FY26 to be the strongest sequential growth quarter for the year, aligning with their guidance of achieving greater than 2x industry growth.- Concall Update

Mphasis: Guidance - The pace of revenue and deal conversion is expected to remain strong, propelled by the Savings-Led Transformation theme, with the direct business trending towards double-digit growth.- Concall Update

 23 Jan 2026 08:51 AM

Mphasis: Guidance - The pace of revenue and deal conversion is expected to remain strong, propelled by the Savings-Led Transformation theme, with the direct business trending towards double-digit growth.- Concall Update

Mphasis: Guidance - DSO is expected to trend progressively down over the course of the 2026 calendar year, and the EBIT margin will be maintained within the 14.75% to 15.75% band.- Concall Update

 23 Jan 2026 08:51 AM

Mphasis: Guidance - DSO is expected to trend progressively down over the course of the 2026 calendar year, and the EBIT margin will be maintained within the 14.75% to 15.75% band.- Concall Update

Mphasis: Guidance - While a detailed FY27 outlook will be provided in the April call, management anticipates the current growth template, observed over the last three quarters, will continue into FY27.- Concall Update

 23 Jan 2026 08:51 AM

Mphasis: Guidance - While a detailed FY27 outlook will be provided in the April call, management anticipates the current growth template, observed over the last three quarters, will continue into FY27.- Concall Update